Last 28 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 4.04 | — | — | — | — | — | 0.52 | 1.99 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.74 | 1254.54 | 644.37 | 368.65 | 10.28 | 28.34 | 0.34 | 0.98 | 1.73 | 0.75 | 0.76 | 2.39 | 3.11 |
| — | +4326.9% | +188416.3% | +37665.3% | +493.4% | +3686.8% | -54.9% | -59.1% | -44.4% | -84.7% | -89.3% | -83.1% | -82.5% | |
| P/B Ratio | 0.51 | 3.92 | 1.36 | 0.87 | 0.47 | 1.01 | 0.91 | 1.85 | 2.58 | 1.35 | 1.76 | 2.09 | 2.18 |
| — | +289.6% | +49.2% | -53.0% | -82.0% | -25.5% | -48.2% | -11.7% | +18.3% | -20.9% | +67.1% | -22.6% | -55.8% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | -0.24 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | -0.18 | -1.04 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Precision BioSciences, Inc.'s operating margin was -158976.9% in Q3 2025, down 37438.0 pp QoQ and down 155283.3 pp YoY. This marks the 6th consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of -90164.6% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 5184.6% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | -5084.6% | -3766.7% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 84.5% | 87.9% | 74.1% | 78.5% |
| — | -5184.6% | -3866.7% | 0.0% | 0.0% | +18.4% | +13.7% | +35.0% | +27.3% | +21.6% | +110.8% | +131.5% | -21.5% | |
| Operating Margin | -38.1% | -158976.9% | -121538.9% | -76248.3% | -3894.4% | -3693.6% | 48.4% | -23.8% | -211.6% | -94.2% | -15.8% | -152.1% | -114.3% |
| — | -4204.1% | -251261.7% | -320117.5% | -1740.7% | -3819.7% | +406.0% | +84.3% | -85.2% | +52.7% | +98.0% | +81.6% | +76.4% | |
| Net Margin | 10.4% | -167476.9% | -130666.7% | -70913.8% | -2781.3% | -2851.6% | 65.6% | 48.8% | -231.4% | -126.0% | -60.5% | -285.4% | -268.8% |
| — | -5773.2% | -199190.2% | -145296.4% | -1101.7% | -2164.0% | +208.6% | +117.1% | +13.9% | +61.3% | +92.6% | +66.4% | +23.6% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 19.0% | -85.9% | -56.4% | -38.9% | -29.3% | -23.5% | 58.5% | 30.6% | -68.0% | -52.4% | -32.2% | -49.8% | -39.3% |
| — | -265.0% | -196.4% | -227.0% | +56.9% | +55.1% | +281.5% | +161.5% | -72.8% | -104.9% | +10.3% | -42.2% | -70.0% | |
| ROA | 4.8% | -21.5% | -20.2% | -15.8% | -12.3% | -10.3% | 18.7% | 5.0% | -10.1% | -9.6% | -6.2% | -11.3% | -11.2% |
| — | -108.9% | -207.9% | -416.3% | -21.9% | -7.8% | +401.6% | +144.0% | +10.0% | -13.5% | +52.2% | +21.0% | -10.0% | |
| ROIC | — | -1442.6% | -1052.1% | -1381.4% | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 62.6% YoY to 3.45x, tightening the short-term liquidity position. Debt/Equity has risen for 6 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.53 | 1.75 | 0.86 | 0.60 | 0.53 | 0.47 | 0.41 | 0.83 | 1.66 | 0.82 | 0.82 | 0.66 | 0.41 |
| — | +274.8% | +109.7% | -27.8% | -67.9% | -43.1% | -49.8% | +26.1% | +301.4% | +152.3% | +203.9% | +431.1% | +313.2% | |
| Debt / EBITDA | — | — | — | — | — | — | 1.21 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.34 | 3.45 | 5.18 | 6.62 | 6.34 | 9.22 | 4.37 | 4.82 | 2.73 | 2.88 | 2.62 | 3.61 | 3.34 |
| — | -62.6% | +18.5% | +37.3% | +132.5% | +220.1% | +66.7% | +33.7% | -18.3% | -21.8% | -42.9% | -21.7% | -25.8% | |
| Quick Ratio | 6.34 | 3.45 | 5.18 | 6.62 | 6.34 | 9.22 | 4.37 | 4.82 | 2.73 | 2.88 | 2.62 | 3.61 | 3.34 |
| — | -62.6% | +18.5% | +37.3% | +132.5% | +220.1% | +66.7% | +33.7% | -18.3% | -21.8% | -42.9% | -21.7% | -25.8% | |
| Interest Coverage | -14.68 | -57.09 | -61.11 | -62.46 | -63.38 | -83.11 | 43.12 | -7.29 | -25.72 | -21.46 | -5.66 | -25.58 | -24.92 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 28 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonPrecision BioSciences, Inc.'s current P/E is 4.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Precision BioSciences, Inc.'s current operating margin is -38.1%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Precision BioSciences, Inc.'s business trajectory between earnings reports.